JSPRW
Jasper Therapeutics IncNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
$-3.84
Beta
3.20
52W High
$0.18
52W Low
$0.02
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Jasper Therapeutics Inc
Jasper Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases, leveraging its proprietary hematopoietic cell transplantation platform. Its lead candidate, JSP191, targets blood disorders and has shown promising results in early clinical trials, suggesting significant potential for improved patient outcomes and safety. With a strong pipeline and a seasoned team of industry professionals, Jasper Therapeutics is positioned to make transformative contributions to the field of cell therapy and regenerative medicine as it advances through clinical development stages.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-80.53M |
| Operating Margin | 0.00% |
| Return on Equity | -230.30% |
| Return on Assets | -88.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.15 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $21.88M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Data last updated: 4/8/2026